---
schema_version: "secwatch.filing_event.v1"
accession: "0000950142-22-000881"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:01:23.933860+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CEO Deepa Prasad resigns effective March 29, 2022; Richard Nelson appointed Interim CEO

## Summary
- Prasad resigns as CEO/President/Board member, will serve as Strategic Advisor for 6 months.
- Prasad receives $325,000 bonus, salary continuation for 15 months, retains 624,659 options.
- Richard Nelson appointed Acting CEO until March 29 then Interim CEO; enters employment agreement.
- Nelson to receive $200k base salary, 100% cash bonus for FY2022, options for 500,000 shares at $0.8060.
- Board amended bylaws to allow appointment of Lead Independent Director.

## SEC filing metadata
- accession: 0000950142-22-000881
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/eh220231317_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950142-22-000881
- JSON: https://secwatch.observer/filing/0000950142-22-000881.json
- Plain text: https://secwatch.observer/filing/0000950142-22-000881.txt

## Key facts
- Executive change
  Deepa Prasad resigned as Chief Executive Officer at vTv Therapeutics Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On February 27, 2022, Ms. Deepa Prasad notified the Board of Directors (the “Board”) of vTv Therapeutics Inc. (the “Company”) of her decision to resign from her positions as Chief Executive Officer, President and Board member, effective as of March 29, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm
- Executive change
  Richard S. Nelson was appointed as Chief Executive Officer at vTv Therapeutics Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On March 1, 2022, the Board appointed Mr. Richard S. Nelson as Acting Chief Executive Officer until the Effective Date, at which time Mr. Nelson will become Interim Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641489/000095014222000881/0000950142-22-000881-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.